Had a quick read of Bauer's yet to be peer reviewed paper, I get a sense that the new additional data being generated by mesoblast will be in line with what is being suggested by Bauer's experiments. Not sure why priming is being treated as some kind of new discovery given Mesoblast have been doing for years in their manufacturing processes. They have also been refining their donor selection criteria over many years (I suspect in a proprietary, commercially sensitive way, given their years of R&D in this area) and likely an issue with Bauer's off the shelf donors from their suppliers. Anyway, it gives me a better sense of FDA's thinking.
https://www.biorxiv.org/content/10.1101/2021.02.23.432501v1.full
Alzheimer drug approved, page-19
-
- There are more pages in this discussion • 225 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.015(1.49%) |
Mkt cap ! $1.164B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | 94.0¢ | $11.76M | 11.90M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 206912 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 37637 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |